A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) subjects (PREDICTRA)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PREDICTRA
- Sponsors AbbVie
- 11 Oct 2017 Planned primary completion date changed from 28 Aug 2017 to 7 May 2019.
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated